Titan Biotech Ltd
Titan Biotech Ltd (TITANBIO) last reported results for the quarter ended Jun 2026, with sales of ₹59 crore and net profit of ₹11 crore. The next scheduled event is a record date on 23 Oct 2026. The stock last traded at ₹385, a market capitalisation of ₹1,591 crore, on a P/E of 47.0. Over the past 52 weeks the stock has ranged between ₹171 and ₹556. Figures are as of 6 Oct 2026 and are not real time.
Titan Biotech Ltd share price and key metrics
- Current price
- ₹385
- Market cap
- ₹1,591 cr
- Stock P/E
- 47.0
- Book value
- ₹43.9
- ROE
- 17.8%
- ROCE
- 22.8%
- Dividend yield
- 0.13%
- 52w high / low
- 556/171
Metrics as of 6 Oct 2026. Not real time.
Track Titan Biotech Ltd
Cruxal reads every Titan Biotech Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Titan Biotech Ltd growth and returns
- 10 Years
- 16%
- 5 Years
- 8%
- 3 Years
- 13%
- TTM
- 37%
- 10 Years
- 33%
- 5 Years
- 0%
- 3 Years
- 6%
- TTM
- 54%
- 10 Years
- 48%
- 5 Years
- 42%
- 3 Years
- 74%
- 1 Year
- 96%
- 10 Years
- 22%
- 5 Years
- 20%
- 3 Years
- 18%
- Last Year
- 18%
Titan Biotech Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹59 cr, up 28.3% from ₹46 cr a year earlier. Net profit was ₹11 cr, up 57.1% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 40 | 38 | 35 | 46 | 54 | 57 | 49 | 59 |
| Expenses | 32 | 33 | 31 | 38 | 45 | 46 | 39 | 47 |
| Operating profit | 8 | 5 | 5 | 9 | 9 | 11 | 10 | 12 |
| OPM % | 19% | 13% | 13% | 19% | 17% | 19% | 20% | 21% |
| Other income | 0 | 2 | 1 | 1 | 1 | 1 | 2 | 2 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 7 | 5 | 5 | 8 | 9 | 11 | 10 | 13 |
| Tax % | 25% | 26% | 25% | 24% | 26% | 26% | 36% | 26% |
| Net profit | 7 | 4 | 4 | 7 | 8 | 9 | 7 | 11 |
| EPS (₹) | 1.62 | 1.06 | 0.98 | 1.66 | 1.88 | 2.07 | 1.63 | 2.63 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Titan Biotech Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 53 | 57 | 65 | 79 | 142 | 124 | 144 | 164 | 156 | 206 | 219 |
| Operating profit | 5 | 7 | 9 | 13 | 46 | 31 | 30 | 34 | 25 | 39 | 42 |
| OPM % | 10% | 12% | 14% | 17% | 32% | 25% | 21% | 21% | 16% | 19% | 19% |
| Net profit | 2 | 3 | 4 | 8 | 32 | 22 | 25 | 25 | 22 | 30 | 34 |
| EPS (₹) | 0.56 | 0.66 | 0.85 | 1.71 | 7.35 | 5.25 | 6.01 | 6.02 | 5.21 | 7.23 | 8.21 |
TTM is the trailing twelve months to the most recent quarter.
Titan Biotech Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| Reserves | 15 | 17 | 24 | 31 | 60 | 78 | 102 | 125 | 145 | 173 |
| Borrowings | 22 | 26 | 24 | 24 | 16 | 9 | 9 | 8 | 3 | 6 |
| Other liabilities | 7 | 7 | 9 | 13 | 16 | 13 | 16 | 15 | 19 | 27 |
| Total liabilities | 52 | 57 | 65 | 76 | 101 | 108 | 135 | 157 | 175 | 214 |
| Fixed assets | 13 | 14 | 29 | 31 | 34 | 35 | 36 | 52 | 57 | 62 |
| CWIP | 9 | 13 | -0 | 0 | 0 | 4 | 13 | 3 | 2 | 2 |
| Investments | -0 | -0 | -0 | -0 | -0 | 4 | 15 | 28 | 33 | 60 |
| Other assets | 30 | 30 | 36 | 45 | 67 | 65 | 70 | 74 | 83 | 90 |
| Total assets | 52 | 57 | 65 | 76 | 101 | 108 | 135 | 157 | 175 | 214 |
As reported by the company. Total assets equal total liabilities by construction.
Titan Biotech Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 0 | 2 | 5 | 6 | 19 | 22 | 21 | 21 | 20 | 30 |
| Cash from investing | -8 | -6 | -4 | -2 | -5 | -16 | -21 | -20 | -10 | -33 |
| Cash from financing | 9 | 0 | -0 | -4 | -11 | -4 | -2 | -3 | -8 | -2 |
| Net cash flow | 1 | -3 | 1 | -0 | 4 | 2 | -2 | -2 | 2 | -4 |
| Free cash flow | -7 | -4 | 1 | 8 | 14 | 8 | 8 | 12 | 12 | 23 |
| CFO / operating profit | 21% | 43% | 74% | 62% | 65% | 93% | 97% | 85% | 103% | 101% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Titan Biotech Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 12% | 13% | 15% | 20% | 58% | 32% | 27% | 25% | 17% | 23% |
| Debtor days | 44 | 49 | 52 | 54 | 46 | 48 | 53 | 42 | 44 | 40 |
| Inventory days | 155 | 202 | 236 | 259 | 177 | 206 | 179 | 208 | 243 | 202 |
| Days payable | 15 | 13 | 24 | 38 | 20 | 25 | 27 | 15 | 36 | 31 |
| Cash conversion cycle | 184 | 239 | 264 | 276 | 203 | 230 | 205 | 234 | 250 | 211 |
| Working capital days | 90 | 108 | 97 | 101 | 88 | 118 | 109 | 111 | 131 | 102 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Titan Biotech Ltd shareholding pattern
Promoters held 55.78% at Jun 2026, broadly unchanged since Jun 2025. DIIs 0.01%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 55.87% | 55.87% | 55.87% | 55.87% | 55.78% | 55.78% | 55.78% | 55.78% |
| DIIs | 0.00% | 0.00% | 0.01% | 0.03% | 0.03% | 0.03% | 0.03% | 0.01% |
| Public | 44.13% | 44.12% | 44.11% | 44.10% | 44.19% | 44.19% | 44.19% | 44.21% |
| No. of shareholders | 15,700 | 16,038 | 16,370 | 16,328 | 16,040 | 16,367 | 17,457 | 18,671 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Upcoming Titan Biotech Ltd events
The next scheduled event is a record date on 23 Oct 2026.
- Record dateRecord date for bonus share allotment
See the full results calendar for every Indian company reporting in the next 30 days.
Cruxal coverage of Titan Biotech Ltd
Titan Biotech Ltd corporate filings
- Titan Biotech Limited announces issuance of 1.03 crore bonus equity shares at Rs. 2 each, with record date set for October 23, 2026Corp. Actionhigh impact
Cruxal's analysis: Titan Biotech Limited has received shareholder approval and regulatory clearance to issue…
Read the full analysis - Certificate under Regn 74(5) of SEBI (DP) Regulations, 2018 for quarter ended September 30, 2026Company Updatelow impact
- Amendment to Clause 5 (Capital Clause) of MOA of Titan Biotech LtdCompany Updatelow impact
Cruxal's analysis: Titan Biotech Ltd has altered the Capital Clause (Clause 5) of its Memorandum of…
Read the full analysis - Titan Biotech Limited Conducts 34th AGM with Full Shareholder Approval on Key ResolutionsAGM/EGMmedium impact
Cruxal's analysis: Titan Biotech Limited held its 34th Annual General Meeting on September 29, 2026, via…
Read the full analysis - Titan Biotech Limited's AGM confirms strategic initiatives including share capital increase, bonus issue, and reappointment of key directors, with no immediate financial surprises.AGM/EGMmedium impact
Cruxal's analysis: Titan Biotech Limited held its 34th AGM on September 29, 2026, via video conferencing…
Read the full analysis - Closure of Trading WindowInsider Trading / SASTlow impact
- Titan Biotech Limited discloses loss of share certificates under SEBI regulationsCompany Updatelow impact
Cruxal's analysis: Titan Biotech Limited has issued a formal disclosure regarding the loss of share…
Read the full analysis - Titan Biotech Ltd announces 34th Annual General Meeting and E-voting scheduleCompany Updatelow impact
Cruxal's analysis: Titan Biotech Ltd has published a newspaper notice regarding its 34th Annual General…
Read the full analysis - Titan Biotech Ltd announces weblink for FY 2025-26 Annual Report and 34th AGM noticeCompany Updatelow impact
Cruxal's analysis: Titan Biotech Ltd has issued a communication to shareholders who have not registered…
Read the full analysis - Titan Biotech Limited Announces 1:4 Bonus Issue and Final Dividend of INR 0.50 per share for FY 2025-26AGM/EGMhigh impact
Cruxal's analysis: Titan Biotech Limited has announced a final dividend of INR 0.50 per equity share (face…
Read the full analysis - Titan Biotech Ltd releases 34th Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Titan Biotech Ltd has filed its 34th Annual Report for the financial year 2025-26. The…
Read the full analysis - Titan Biotech Limited announces 34th Annual General Meeting via VC/OAVMCompany Updatelow impact
Cruxal's analysis: Titan Biotech Limited has published a newspaper advertisement regarding the convening of…
Read the full analysis - Titan Biotech Limited fixes September 22, 2026, as Record Date for final dividend of INR 0.50 per shareCorp. Actionlow impact
Cruxal's analysis: Titan Biotech Limited has officially announced Tuesday, September 22, 2026, as the record…
Read the full analysis - Titan Biotech Limited Announces AGM Date and Record Date for Final Dividend PaymentAGM/EGMlow impact
Cruxal's analysis: Titan Biotech Limited has scheduled its 34th Annual General Meeting for September 29…
Read the full analysis - Titan Biotech Ltd announces 34th Annual General Meeting, Book Closure, and E-Voting scheduleCorp. Actionlow impact
Cruxal's analysis: Titan Biotech Ltd has scheduled its 34th Annual General Meeting (AGM) and fixed the…
Read the full analysis - Titan Biotech Limited Announces 1:4 Bonus Issue and Increase in Authorized Share CapitalBoard Meetinghigh impact
Cruxal's analysis: Titan Biotech Limited has approved a bonus issue of equity shares in a 1:4 ratio…
Read the full analysis - Titan Biotech Limited to consider proposal for bonus share issuance on September 03, 2026Board Meetinghigh impact
Cruxal's analysis: Titan Biotech Limited has announced a board meeting scheduled for September 03, 2026, to…
Read the full analysis - Closure of Trading WindowInsider Trading / SASTlow impact
- Titan Biotech Limited reports Q1 FY2027 financial results with 21% operating marginCompany Updatelow impact
Cruxal's analysis: Titan Biotech Limited has released its unaudited financial results for the quarter ended…
Read the full analysis - Titan Biotech Limited reports strong Q1 FY27 performance with consolidated net profit of 10.86 croreResulthigh impact
Cruxal's analysis: Titan Biotech Limited has announced its unaudited financial results for the quarter ended…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.